Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3031524 | 0.89 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL623077 | 0.87 | EGLN1 (0.60) | EGLN1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL622053 | 0.87 | EGLN1 (0.60) | EGLN1 | |
| SCHEMBL13219098 | 0.85 | EGLN1 (0.56) | EGLN1KDM4EALDH1A1HPGDEGLN3 | |
| SCHEMBL3031018 | 0.84 | EGLN1 (0.55) | EGLN1EGLN3 | |
| SCHEMBL3020604 | 0.84 | EGLN1 (0.55) | EGLN1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3038979 | 0.84 | EGLN1 (0.55) | EGLN1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL16857762 | 0.83 | EGLN1 (0.76) | EGLN1 | |
| SCHEMBL621819 | 0.82 | EGLN1 (0.54) | EGLN1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3035059 | 0.82 | EGLN1 (0.53) | EGLN1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975062-B2 | 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV | 2021-04-13 | — | — | US | disclosed |
| US-20200095234-A1 | 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-26 | — | — | US | disclosed |
| US-10246442-B2 | 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-02 | — | — | US | disclosed |
| US-20180148435-A9 | 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-31 | — | — | US | disclosed |
| US-20170320859-A1 | 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-9573940-B2 | 4-aminoquinazolinyl-2-yl-1-pyrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-21 | — | — | US | disclosed |
| US-20150197507-A1 | 4-Aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-16 | — | — | US | disclosed |
| EP-2396316-B1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | disclosed |
| US-9006251-B2 | 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors | JANSSEN PHARAMCEUTICA NV (BE) | 2015-04-14 | — | — | US | disclosed |
| US-8937078-B2 | Quinazolinones as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-20140309215-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARAMCEUTICA NV (BE) | 2014-10-16 | — | — | US | disclosed |
| US-8796263-B2 | 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-05 | — | — | US | disclosed |
| EP-2603502-B1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | disclosed |
| EP-2603502-A1 | 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2013-06-19 | — | — | EP | disclosed |
| US-20130143871-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-06 | — | — | US | disclosed |
| WO-2012021830-A1 | 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-16 | — | — | WO | disclosed |
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320859-A1 | 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885KDM4E 156/4885ALDH1A1 171/4885 |
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | EGLN1 7/4885KDM4E 719/4885ALDH1A1 108/4885 |
| US-10975062-B2 | 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885KDM4E 192/4885ALDH1A1 132/4885 |
| US-20200095234-A1 | 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885KDM4E 192/4885ALDH1A1 132/4885 |
| US-20180148435-A9 | 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885KDM4E 156/4885ALDH1A1 171/4885 |
| US-20140309215-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 7/4885KDM4E 171/4885ALDH1A1 84/4885 |
| US-20150197507-A1 | 4-Aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885KDM4E 192/4885ALDH1A1 132/4885 |
| US-10246442-B2 | 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885KDM4E 156/4885ALDH1A1 171/4885 |
| US-20130143871-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 7/4885KDM4E 171/4885ALDH1A1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.